INSIGHT: An explorative, single centre, open-label, phase I study to evaluate the feasibility and safety of intra-tumoural, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumour entities

Trial Profile

INSIGHT: An explorative, single centre, open-label, phase I study to evaluate the feasibility and safety of intra-tumoural, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumour entities

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2017

At a glance

  • Drugs IMP 321 (Primary) ; IMP 321 (Primary) ; IMP 321 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms INSIGHT
  • Most Recent Events

    • 09 Jul 2017 According to Prima BioMed media release, company has recieved regulatory (German Federal Ministry of Health) and ethical approvals for initiation of this trial.
    • 15 Jul 2016 New trial record
    • 12 Jul 2016 According to Prima BioMed media release, study will commence subject to receiving the necessary approvals from the competent regulatory authority and ethics committee.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top